RMTI - Rockwell Medical Inc Stock Price, Fair Value and News

1.75USD+0.01 (+0.57%)Delayed

Market Summary

USD1.75+0.01

Delayed

0.57%

RMTI Stock Price

View Fullscreen

RMTI RSI Chart

RMTI Valuation

Market Cap

53.1M

Price/Earnings (Trailing)

-6.3

Price/Sales (Trailing)

0.61

EV/EBITDA

-2.28

Price/Free Cashflow

-6.71

RMTI Price/Sales (Trailing)

RMTI Profitability

EBT Margin

-31.99%

Return on Equity

-40.79%

Return on Assets

-16.6%

Free Cashflow Yield

-14.91%

RMTI Fundamentals

RMTI Revenue

Revenue (TTM)

86.6M

Rev. Growth (Yr)

15.29%

Rev. Growth (Qtr)

2.64%

RMTI Earnings

Earnings (TTM)

-8.4M

Earnings Growth (Yr)

1.09%

Earnings Growth (Qtr)

-14.48%

Breaking Down RMTI Revenue

Last 7 days

6.7%

Last 30 days

18.2%

Last 90 days

29.6%

Trailing 12 Months

-25.8%

How does RMTI drawdown profile look like?

RMTI Financial Health

Current Ratio

1.79

Debt/Equity

0.4

Debt/Cashflow

-0.96

RMTI Investor Care

Shares Dilution (1Y)

120.58%

Diluted EPS (TTM)

-0.35

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	86.6M	0	0	0
2023	76.4M	75.8M	80.8M	83.6M
2022	62.6M	66.1M	68.8M	72.8M
2021	61.8M	61.1M	61.8M	61.9M
2020	61.6M	62.7M	62.5M	62.2M
2019	64.0M	63.9M	62.7M	61.3M
2018	57.7M	59.3M	61.4M	63.4M
2017	54.2M	54.0M	55.9M	57.3M
2016	55.1M	55.6M	54.0M	53.3M
2015	55.1M	55.0M	55.7M	55.4M
2014	53.0M	53.1M	53.7M	54.2M
2013	50.2M	51.0M	51.4M	52.4M
2012	47.7M	48.0M	48.7M	49.8M
2011	57.9M	54.2M	51.4M	49.0M
2010	0	56.3M	57.9M	59.6M
2009	0	0	0	54.7M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Rockwell Medical Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 17, 2024	timmins megan c.	sold (taxes)	-4,391	1.4	-3,137	evp, clo and secretary
Mar 17, 2024	strobeck mark	sold (taxes)	-8,541	1.4	-6,101	president and ceo
Mar 14, 2024	neri jesse	acquired	-	-	33,330	svp, finance
Mar 14, 2024	timmins megan c.	acquired	-	-	50,000	evp, clo and secretary
Mar 14, 2024	strobeck mark	acquired	-	-	100,000	president and ceo
Oct 16, 2023	lau joan	acquired	-	-	25,000	-
May 23, 2023	radie robert s	acquired	-	-	24,715	-
May 23, 2023	nissenson allen	acquired	-	-	24,715	-
May 23, 2023	smiley andrea heslin	acquired	-	-	24,715	-

Which funds bought or sold RMTI recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	COMERICA BANK	unchanged	-	-37.00	271	-%
May 16, 2024	JANE STREET GROUP, LLC	sold off	-100	-61,007	-	-%
May 15, 2024	CITADEL ADVISORS LLC	added	139	49,561	94,620	-%
May 15, 2024	STATE STREET CORP	unchanged	-	-17,090	123,345	-%
May 15, 2024	Royal Bank of Canada	reduced	-74.78	-	-	-%
May 15, 2024	TWO SIGMA INVESTMENTS, LP	sold off	-100	-90,215	-	-%
May 15, 2024	MARSHALL WACE, LLP	reduced	-44.13	-168,537	162,395	-%
May 15, 2024	Tower Research Capital LLC (TRC)	added	72.61	2,621	7,699	-%
May 15, 2024	Cetera Advisor Networks LLC	unchanged	-	-3,249	23,451	-%
May 15, 2024	ARMISTICE CAPITAL, LLC	added	41.99	864,922	4,365,200	0.06%

Are Funds Buying or Selling RMTI?

Are funds buying RMTI calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own RMTI

No. of Funds

Unveiling Rockwell Medical Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	armistice capital, llc	9.99%	3,380,534	SC 13G/A
Sep 06, 2023	richmond brothers, inc.	1%	55,510	SC 13D/A
Feb 23, 2023	richmond brothers, inc.	4.47%	519,980	SC 13G
Feb 14, 2023	davita inc.	9.9%	1,278,173	SC 13G/A
Feb 14, 2023	armistice capital, llc	9.99%	1,215,714	SC 13G
Jun 23, 2022	richmond brothers, inc.	6.3%	595,075	SC 13D/A
Apr 18, 2022	davita inc.	7.4%	7,500,000	SC 13G
Feb 24, 2022	blackrock inc.	1.0%	959,884	SC 13G/A
Feb 16, 2021	cvi investments, inc.	-	4,914,536	SC 13G/A
Feb 02, 2021	blackrock inc.	5.1%	4,790,950	SC 13G

Recent SEC filings of Rockwell Medical Inc

View All Filings

Date Filed	Form Type	Document
May 14, 2024	8-K	Current Report
May 14, 2024	8-K	Current Report
May 14, 2024	10-Q	Quarterly Report
May 03, 2024	SCHEDULE 13G	SCHEDULE 13G
Apr 15, 2024	DEF 14A	DEF 14A
Apr 15, 2024	ARS	ARS
Mar 21, 2024	8-K	Current Report
Mar 21, 2024	8-K	Current Report
Mar 21, 2024	10-K	Annual Report
Mar 19, 2024	4	Insider Trading

Peers (Alternatives to Rockwell Medical Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
JNJ	372.2B	85.6B	6.82%	-1.69%	9.67	4.35	5.68%	202.39%
MRK	332.3B	61.4B	4.65%	15.09%	144.1	5.41	6.11%	-82.30%
AMGN	167.7B	29.5B	18.35%	39.38%	44.55	5.68	12.76%	-52.47%
PFE	162.3B	57.8B	12.71%	-21.46%	129.52	2.81	76.51%	-86.81%
GILD	84.4B	27.4B	1.23%	-13.37%	174.21	3.07	1.51%	-91.32%
TEVA	18.4B	16.0B	23.52%	97.09%	-37.29	1.15	7.23%	71.10%
MID-CAP
ALKS	4.1B	1.7B	0.67%	-19.91%	9.41	2.37	54.01%	364.56%
PRGO	4.1B	4.6B	-0.70%	-10.77%	-528.11	0.89	-0.06%	94.55%
BHC	2.5B	9.0B	-21.94%	-21.03%	-5.45	0.28	10.01%	-27.45%
AMPH	2.1B	676.2M	8.56%	-0.82%	13.75	3.14	30.38%	66.04%
SMALL-CAP
TLRY	1.5B	743.2M	15.12%	-18.85%	-4.35	2.06	24.65%	80.36%
TXMD	25.8M	1.3M	18.52%	-47.17%	-3.49	19.84	-98.14%	-104.71%
ACRX	18.4M	89.6M	6.93%	25.60%	-1.29	0.19	287.27%	-129.41%
AGRX	2.5M	21.5M	2.70%	-90.89%	-0.32	0.12	66.16%	61.83%
ACOR	633.5K	115.7M	-50.00%	-97.38%	0	0.01	-2.22%	-352.48%

Rockwell Medical Inc News

Latest updates

Rockwell Medical Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	2.6%	22,676,000	22,093,000	23,771,000	18,080,000	19,668,000	19,313,000	18,691,000	18,682,000	16,124,000	15,332,500	15,988,000	15,137,000	15,473,000	15,164,000	15,280,000	15,896,000	15,857,000	15,491,000	15,407,000	14,846,000	15,559,000
Gross Profit	6.8%	3,064,000	2,870,000	2,202,000	1,033,000	2,599,000	2,340,500	777,000	1,745,000	-786,000	-2,230,500	-329,000	-262,000	401,000	385,000	346,000	881,000	1,113,000	1,112,230	-17,000	733,149	1,010,392
S&GA Expenses	9.8%	594,000	541,000	556,000	530,000	498,000	351,000	762,000	526,000	455,000	873,000	1,541,000	1,468,000	1,851,000	2,132,500	1,669,000	1,997,000	2,073,000	1,901,313	1,827,000	2,218,997	3,102,378
R&D Expenses	-	18,000	-	494,000	167,000	278,000	-	469,000	926,000	1,567,000	-	1,221,000	2,416,000	1,809,000	-	1,745,000	1,616,000	1,822,000	-	1,475,000	2,958,276	497,276
EBITDA Margin	5.2%	-0.27	-0.29	-0.31	-0.34	-0.33	-0.35	-0.36	-0.38	-0.40	-0.40	-0.40	-0.40	-0.40	-0.40	-	-	-	-	-	-	-
Interest Expenses	-61.1%	431,000	1,108,000	411,000	395,000	387,000	437,000	476,000	485,000	540,000	587,500	609,000	583,000	581,000	590,000	666,000	521,000	102,000	9,000	16,000	-	-
EBT Margin	3.5%	-0.32	-0.33	-0.34	-0.37	-0.36	-0.38	-0.40	-0.42	-0.44	-0.45	-0.45	-0.45	-0.45	-0.45	-	-	-	-	-	-	-
Net Income	-14.5%	-1,731,000	-1,512,000	-1,872,000	-3,305,000	-1,750,000	-2,361,000	-4,190,000	-4,967,000	-7,162,000	-8,941,000	-7,581,000	-8,400,000	-7,752,000	-8,663,000	-7,350,000	-6,893,000	-7,984,000	-7,302,000	-7,855,000	-10,292,000	-8,679,000
Net Income Margin	3.7%	-0.10	-0.10	-0.11	-0.15	-0.17	-0.26	-0.37	-0.43	-0.51	-0.53	-0.52	-0.53	-0.50	-0.50	-	-	-	-	-	-	-
Free Cashflow	-5481.4%	-2,400,000	-43,000	-3,753,000	-1,716,000	-3,900,000	-112,000	-1,102,000	-5,904,000	-9,811,000	-9,026,000	-7,075,000	-4,938,000	-12,495,000	-8,569,000	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-2.8%	51.00	52.00	53.00	38.00	40.00	47.00	54.00	59.00	37.00	49.00	59.00	64.00	69.00	78.00	85.00	59.00	67.00	44.00	48.00	57.00	49.00
Current Assets	-7.2%	27.00	29.00	28.00	28.00	30.00	35.00	42.00	47.00	25.00	35.00	46.00	52.00	59.00	69.00	78.00	52.00	59.00	37.00	41.00	48.00	40.00
Cash Equivalents	-26.1%	7.00	9.00	8.00	9.00	11.00	10.00	13.00	31.00	10.00	13.00	23.00	32.00	36.00	49.00	57.00	27.00	37.00	12.00	14.00	21.00	21.00
Inventory	3.4%	6.00	6.00	5.00	6.00	6.00	6.00	5.00	5.00	6.00	4.00	4.00	5.00	4.00	4.00	4.00	5.00	4.00	4.00	4.00	4.00	4.00
Net PPE	-4.2%	6.00	6.00	7.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	3.00	3.00	2.00	3.00	3.00	2.00	2.00	2.00	3.00	3.00	3.00
Goodwill	0%	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Liabilities	-2.6%	30.00	31.00	31.00	29.00	28.00	33.00	38.00	39.00	42.00	46.00	48.00	45.00	43.00	44.00	43.00	42.00	45.00	24.00	24.00	27.00	29.00
Current Liabilities	-10.1%	15.00	17.00	21.00	17.00	15.00	18.00	19.00	19.00	20.00	21.00	22.00	34.00	11.00	13.00	13.00	11.00	13.00	12.00	12.00	15.00	16.00
Long Term Debt	-0.3%	8.00	8.00	3.00	5.00	6.00	8.00	9.00	10.00	12.00	13.00	14.00	-	21.00	21.00	21.00	21.00	21.00	-	-	-	-
LT Debt, Current	-	-	-	6.00	5.00	3.00	2.00	5.00	5.00	7.00	7.00	7.00	21.00	-	-	-	-	-	-	-	-	-
LT Debt, Non Current	-100.0%	-	8.00	3.00	5.00	6.00	8.00	9.00	10.00	12.00	13.00	14.00	-	21.00	21.00	21.00	21.00	21.00	-	-	-	-
Shareholder's Equity	-3.0%	21.00	21.00	22.00	10.00	13.00	14.00	16.00	20.00	-	3.00	11.00	18.00	26.00	34.00	42.00	16.00	22.00	20.00	24.00	30.00	20.00
Retained Earnings	-0.4%	-398	-397	-395	-393	-390	-388	-386	-382	-377	-370	-361	-353	-345	-337	-328	-321	-314	-306	-299	-291	-281
Additional Paid-In Capital	0.3%	420	418	417	403	403	403	402	402	372	373	372	372	371	372	371	338	336	327	323	-	-
Shares Outstanding	0.7%	29.00	29.00	28.00	17.00	13.00	12.00	11.00	9.00	9.00	9.00	9.00	9.00	9.00	9.00	-	-	-	-	-	-	-
Float	-	-	-	-	91.00	-	-	-	11.00	-	-	-	29.00	-	-	-	112	-	-	-	153	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-5481.4%	-2,400	-43.00	-3,753	-1,716	-3,900	-112	-1,102	-5,904	-9,811	-9,026	-7,075	-4,938	-12,495	-8,569	-4,918	-9,616	-6,538	-5,300	-6,175	-10,354	-5,423
Share Based Compensation	15.1%	251	218	212	309	193	220	177	97.00	-179	385	361	433	-236	751	250	-1,461	935	1,057	876	1,501	1,517
Cashflow From Investing	-106.9%	-139	2,008	-10,291	-64.00	5,302	3,218	-14,696	-51.00	9,133	540	-1,364	1,647	-512	637	1,875	-1,886	2,586	172	-1,141	-7,357	3,577
Cashflow From Financing	124.0%	178	-742	12,845	-130	-631	-5,984	-2,002	26,823	-2,687	-1,624	-549	-6.00	-	-1.00	32,960	800	29,557	2,502	321	18,210	52.00

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

RMTI Income Statement

2024-03-31

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Net Sales	$ 22,676	$ 19,668
Cost of Sales	19,612	17,069
Gross Profit	3,064	2,599
Research and Product Development	18	278
Selling and Marketing	594	498
General and Administrative	3,776	3,250
Operating Loss	(1,324)	(1,427)
Other Expense:
Interest Expense	(431)	(387)
Interest Income	24	64
Total Other Expense, net	(407)	(323)
Net Loss	$ (1,731)	$ (1,750)
Basic Net Loss per Share (in dollars per share)	$ (0.06)	$ (0.10)
Diluted Net Loss per Share (in dollars per share)	$ (0.06)	$ (0.10)
Basic Weighted Average Shares Outstanding (in shares)	29,327,204	18,359,940
Diluted Weighted Average Shares Outstanding (in shares)	29,327,204	18,359,940

RMTI Balance Sheet

2024-03-31

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
ASSETS
Cash and Cash Equivalents	$ 6,642	$ 8,983
Investments Available-for-Sale	1,977	1,952
Accounts Receivable, net	11,094	10,901
Inventory, net	6,073	5,871
Prepaid and Other Current Assets	910	1,063
Total Current Assets	26,696	28,770
Property and Equipment, net	6,134	6,402
Inventory, Non-Current	178	178
Right of Use Assets - Operating, net	3,884	2,713
Right of Use Assets - Financing, net	1,762	1,903
Intangible Assets, net	10,621	10,759
Goodwill	921	921
Other Non-Current Assets	527	527
Total Assets	50,723	52,173
LIABILITIES AND STOCKHOLDERS’ EQUITY
Accounts Payable	4,919	4,516
Accrued Liabilities	5,253	7,149
Deferred Consideration - Current	2,500	2,500
Lease Liabilities - Operating - Current	1,464	1,381
Lease Liabilities - Financing - Current	566	558
Deferred License Revenue - Current	46	46
Insurance Financing Note Payable	0	244
Customer Deposits	201	243
Total Current Liabilities	14,949	16,637
Lease Liabilities-Operating - Long-Term	2,504	1,433
Lease Liabilities-Financing - Long-Term	1,384	1,530
Term Loan - Long-Term, net of issuance costs	8,265	8,293
Deferred License Revenue - Long-Term	464	475
Deferred Consideration - Long-Term	2,500	2,500
Long Term Liability - Other	14	14
Total Liabilities	30,080	30,882
Stockholders’ Equity:
Preferred Stock, $0.0001 par value, 2,000,000 shares authorized; 15,000 shares issued and outstanding at March 31, 2024 and December 31, 2023	0	0
Common Stock, $0.0001 par value; 170,000,000 shares authorized; 29,556,474 and 29,130,607 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	3	3
Additional Paid-in Capital	419,545	418,487
Accumulated Deficit	(398,929)	(397,198)
Accumulated Other Comprehensive Income (Loss)	24	(1)
Total Stockholders’ Equity	20,643	21,291
Total Liabilities and Stockholders’ Equity	$ 50,723	$ 52,173

About Rockwell Medical Inc

Rockwell Medical, Inc., together with its subsidiaries, operates as a healthcare company that engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. The company offers Triferic Dialysate and Triferic AVNU which are indicated to maintain hemoglobin in patients undergoing hemodialysis. It also manufactures, sells, delivers, and distributes hemodialysis concentrates, such as CitraPure citric acid concentrate, Dri-Sate dry acid concentrate, RenalPure liquid acid concentrate, dry acid concentrate mixer, and RenalPure and SteriLyte powder bicarbonate concentrate; and ancillary products, including cleaning agents, 6% bleach for disinfection, citric acid descale, filtration salts, and other supplies used by hemodialysis providers. The company's dialysis concentrate products are used to maintain human life by removing toxins and replacing critical nutrients in the dialysis patient's bloodstream. It is also developing other therapeutic product candidates for the treatment of hospitalized patients with acute heart failure; and home infusion therapy that allows patients to receive intravenous medications at home. Its target customers include medium and small sized dialysis chains and independent dialysis centers. Rockwell Medical, Inc. was incorporated in 1996 and is headquartered in Wixom, Michigan.

CEO	Dr. Mark Strobeck Ph.D.
WEBSITE	rockwellmed.com
INDUSTRY	Pharmaceuticals
EMPLOYEES	253

Rockwell Medical Inc Frequently Asked Questions

What is the ticker symbol for Rockwell Medical Inc? What does RMTI stand for in stocks?

RMTI is the stock ticker symbol of Rockwell Medical Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Rockwell Medical Inc (RMTI)?

As of Fri May 17 2024, market cap of Rockwell Medical Inc is 53.05 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of RMTI stock?

You can check RMTI's fair value in chart for subscribers.

What is the fair value of RMTI stock?

You can check RMTI's fair value in chart for subscribers. The fair value of Rockwell Medical Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Rockwell Medical Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for RMTI so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Rockwell Medical Inc a good stock to buy?

The fair value guage provides a quick view whether RMTI is over valued or under valued. Whether Rockwell Medical Inc is cheap or expensive depends on the assumptions which impact Rockwell Medical Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for RMTI.

What is Rockwell Medical Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, RMTI's PE ratio (Price to Earnings) is -6.3 and Price to Sales (PS) ratio is 0.61. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. RMTI PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Rockwell Medical Inc's stock?

In the past 10 years, Rockwell Medical Inc has provided -0.161 (multiply by 100 for percentage) rate of return.